Unfortunately I've lost my DCF and will have to start from scratch when I have time. It was roughly 3x underpriced with modest revenue growth and a 12% discount rate from memory.
Competitive landscape is a bit crowded. I think they're (weak) competitive advantages are brand - they've been around for awhile and are trusted in automotive and management having put hundreds of thousands of $ of their own money to buy on market. If you're unfamiliar with the company this was an activist led takeover.
Competitors I've come across and very brief notes:
SMX - Financials were poor, they pay a 2.2% royalty on gross revenues until 2045 to Soreq Nuclear Research Center and it can only be used for civilian uses (they're product can't be sold to/used in fuels, oil, crude oil & other petroleum products).
DTZ - revenue growth looked good
YPB - no notes
TZL - auditor has raised "going concern"
Hope that helps and would love to hear if anyone else has done a valuation.
- Forums
- ASX - By Stock
- DDT
- Its time for change and its on finally on the way
Its time for change and its on finally on the way, page-42
Featured News
Add DDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.843M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 12140 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 1838064 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 12140 | 0.004 |
9 | 3607617 | 0.003 |
10 | 8819527 | 0.002 |
7 | 11551008 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 1838064 | 4 |
0.006 | 898467 | 4 |
0.007 | 1462185 | 4 |
0.008 | 700000 | 2 |
0.009 | 848900 | 3 |
Last trade - 10.02am 12/11/2024 (20 minute delay) ? |
Featured News
DDT (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online